Association between spironolactone use and COVID-19 outcomes in population-scale claims data: a retrospective cohort study

Henry C. Cousins, Russ B. AltmanmedRxiv 2023 · DOI

TL;DR

This retrospective study of nearly 900,000 patients suggests that spironolactone—a common, inexpensive diuretic—is associated with an 18% reduction in the risk of needing a ventilator and a 12% reduction in mortality for hospitalized COVID-19 patients. The protective effect was most pronounced in men and younger patients, supporting the theory that the drug works by blocking androgen-dependent pathways the virus uses to enter cells.

What Problem Does This Paper Address?

While vaccines have significantly reduced the severity of COVID-19, the search for effective, low-cost, and widely available treatments remains critical—especially as new variants emerge. Repurposing existing drugs is a faster and cheaper route than developing new antivirals.

Spironolactone has long been a candidate for repurposing because of its dual action: it blocks the mineralocorticoid receptor (affecting blood pressure) and acts as an androgen antagonist (blocking male hormones). Since the SARS-CoV-2 virus relies on specific host proteins—namely ACE2 and TMPRSS2—to enter cells, and since TMPRSS2 is regulated by androgens, researchers hypothesized that spironolactone could act as a "shield" against viral entry. Previous studies were too small to be conclusive; this paper seeks to provide definitive population-scale evidence.

Methods

The researchers conducted a retrospective cohort study using insurance claims data. To ensure the comparison between spironolactone users and non-users was fair, they employed two robust statistical techniques:

  • Propensity Score Matching (PSM): They created "twins" in the dataset—matching patients who took the drug with those who didn't based on age, gender, BMI, and a wide array of comorbidities (like heart failure, diabetes, and lung disease).
  • Multivariable Logistic Regression: A secondary model used to control for variables without matching, serving as a cross-check for the PSM results.

They also used vaccination status as a "study-level control" to benchmark the drug's effectiveness against a known protective factor.

Datasets

The study utilized the Komodo Healthcare Map, a massive database of deidentified medical and pharmaceutical claims from public and private payers in the U.S.

  • Scale: The database covers over 325 million unique patients.
  • Study Population: 898,303 eligible patients hospitalized with COVID-19 between March 2020 and June 2022.
  • Exposure Group: 16,324 patients who had a spironolactone prescription within 180 days prior to hospitalization.

Key Insights and Ideas

  • The "Androgen Hypothesis" Gains Weight: The drug was significantly more effective in men and younger patients (ages 15-59). Because these groups typically have higher androgen levels, the results strongly suggest that spironolactone’s protective effect is linked to its anti-androgenic properties.
  • Variant-Specific Efficacy: The protective effect was diminished during the Omicron wave. This is a fascinating "aha moment" because biological research has shown that the Omicron variant relies less on the TMPRSS2 (androgen-dependent) pathway for cell entry compared to earlier variants like Delta.
  • Benchmarking Against Vaccines: In a clever move to provide context, the authors found that spironolactone’s protective effect against ventilation was roughly 64% as strong as the effect of having at least one vaccine dose.

Key Results

  • Ventilation: Spironolactone use was associated with an 18% reduction in the odds of requiring mechanical ventilation (OR 0.82; 95% CI: 0.75-0.88).
  • Mortality: The drug was associated with a 12% reduction in the odds of death during hospitalization (OR 0.88; 95% CI: 0.78-0.99).
  • Subgroup Strength: In the 15-59 age group, the reduction in ventilation odds was even higher, at approximately 22-27% depending on the model used.
  • Consistency: The results remained significant across multiple sensitivity analyses, including different "windows" of drug exposure (90 days vs. 360 days).

Limitations and Future Work

The authors acknowledge several key limitations inherent in claims-based research:

  • Correlation vs. Causation: As an observational study, it cannot prove that spironolactone caused the better outcomes, only that they are associated.
  • Adherence: Claims data shows a prescription was filled, but it doesn't guarantee the patient actually took the medication as prescribed.
  • Unmodeled Confounders: While they controlled for many factors, there could be "hidden" differences between people prescribed spironolactone and those who aren't.
  • Future Direction: The authors conclude that these findings are strong enough to justify large-scale randomized controlled trials (RCTs) to formally establish spironolactone’s therapeutic role in treating COVID-19.

Summary updated

Abstract

Spironolactone use was associated with a protective effect against ventilation and mortality following COVID-19 infection, amounting to up to 64% of the protective effect of vaccination against ventilation and consistent with an androgen-dependent mechanism. The findings warrant initiation of large-scale randomized controlled trials to establish a potential therapeutic role for spironolactone in COVID-19 patients.
BibTeX
@misc{cousins2023association,
  author = {Henry C. Cousins and Russ B. Altman},
  title = {{Association between spironolactone use and COVID-19 outcomes in population-scale claims data: a retrospective cohort study}},
  year = {2023},
  doi = {10.1101/2023.02.28.23286515},
  howpublished = {medRxiv},
}
Figure